Ignite Creation Date:
2024-05-05 @ 11:31 PM
Last Modification Date:
2024-10-26 @ 10:34 AM
Study NCT ID:
NCT01340898
Status:
COMPLETED
Last Update Posted:
2019-08-06
First Post:
2011-04-14
Brief Title:
Immunogenicity and Safety Study of GSK Biologicals Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Immunogenicity and Safety Study of GSK Biologicals Meningococcal Conjugate Vaccine GSK 134612 When Co-administered With Routine Vaccines in Healthy Infants and Toddlers
Status:
COMPLETED
Status Verified Date:
2019-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK 134612 in healthy infants when co-administered with other infant vaccines on three different dose schedules
Detailed Description:
This protocol has been updated following Protocol Amendment 1 date 26 July 2011 leading to the update of enrollment a secondary outcome measure intervention and exclusion criteria sections
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2013-002537-37 | EUDRACT_NUMBER | None | None |